A study was undertaken to investigate compliance in patients receiving growth hormone treatment. Two hundred patients completed a questionnaire designed to establish understanding about and compliance with treatment; 50% of our patients failed to comply with ali aspects of their treatment. Failure to respond to treatment seems to be associated with poor compliance. (Arch Dis Child 1993;68:91-3) Embarking on a course of recombinant human growth hormone (rhGH) treatment is a major commitment not only for the child and parents but also for the health care team. rhGH is administered by subcutaneous injection on a daily basis, often for a period of time stretching over many years. The initial perception about the treatment may effect subsequent compliance with the treatment regimen.
50% of our patients failed to comply with ali aspects of their treatment. Failure to respond to treatment seems to be associated with poor compliance. (Arch Dis Child 1993; 68:91-3) Embarking on a course of recombinant human growth hormone (rhGH) treatment is a major commitment not only for the child and parents but also for the health care team. rhGH is administered by subcutaneous injection on a daily basis, often for a period of time stretching over many years. The initial perception about the treatment may effect subsequent compliance with the treatment regimen.
We had suspected for some time that some of our patients for whom we had prescribed rhGH were not complying fully with their therapeutic regimen. To investigate this we designed a questionnaire to assess the level ofunderstanding about and compliance with treatment.
Methods and results
Consecutive patients attending the paediatric endocrinology clinic of the Middlesex Hospital were asked if they were receiving rhGH and, if they were, whether the person responsible for administering the hormone would complete our questionnaire (appendix). We studied understanding of the treatment regimen and compliance with the treatment by combining answers from several of the questions that were designed to obtain the information in different ways.
Two hundred patients accepted the questionnaire and none refused. Of the patients who accepted only 188 were on rhGH; the remainder were receiving an assortment of other treatments including somatostatin and testosterone (Sustanon, Organon We were disturbed to discover from this survey that more than 50% of our patients failed to comply with some aspects of their treatment regimen. The method for mixing the rhGH certainly caused problems to many of our patients and their families, thus confirming previous suspicions. ' The advent of convenience preparations may well circumvent this problem. A more important factor may well be the involvement of a specific member of the health care team experienced in the administration of growth hormone and in the methods necessary to gain the cooperation and confidence of children.
We would like to thank Kabi Pharmacia for financial support that enabled us to undertake this study. Normal tissue showed NADPH diaphorase activity in the nerve fibres of both the circular and longitudinal muscle and in the nerves of the myenteric plexus. In pyloric stenosis, however, the enzyme was absent from the nerves of the circular muscle although still present in the longitudinal muscle and in the myenteric plexus. The nerves of the circular muscle were also morphologically abnormal.
Babies with pyloric stenosis, therefore, lack the enzyme (NO synthase) necessary for the production of NO in the nerves of the circular muscle of the pylorus. This may explain the inability of the pyloric muscle to relax and the work raises the possibility that an effective medical treatment for pyloric stenosis could be developed. 
